510(k) device
A1AT Genotyping Test
Progenika Biopharma S.A., A Grifols Company · Serpina1 Variant Detection System (PZH, Class II) · First FDA decision Nov 11, 2017, newest May 13, 2021COPD and emphysemaGenetic and newborn screening
Last checked: Nov 21, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
3
510(k) pathway
Device trials
0
Naming "A1AT Genotyping"
MAUDE reports
0
Brand "A1AT Genotyping", since 2015
PubMed studies
9
Mentioning "A1AT Genotyping"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing A1AT Genotyping Test
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 3 of 3 decisions filed under this name.
- A1AT Genotyping Test510(k)
K211115 · Decided May 13, 2021 · 29 days after receipt
Device type: Serpina1 Variant Detection System (PZH) · Laboratory Medicine & Pathology
2 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- MolDX: Genome-Wide Molecular Methodologies for the Detection of Copy Number Alterations and Structural Variants in Hematologic NeoplasmsProposed local determinationProposedDL40474WPS Insurance CorporationUpdated Sep 17, 2026
- MolDX: Genome-Wide Molecular Methodologies for the Detection of Copy Number Alterations and Structural Variants in Hematologic NeoplasmsProposed local determinationProposedDL40407Palmetto GBAUpdated Aug 21, 2026
- MolDX: Genome-Wide Molecular Methodologies for the Detection of Copy Number Alterations and Structural Variants in Hematologic NeoplasmsProposed local determinationProposedDL40431CGS Administrators, LLCUpdated Aug 21, 2026
- MolDX: Genome-Wide Molecular Methodologies for the Detection of Copy Number Alterations and Structural Variants in Hematologic NeoplasmsProposed local determinationProposedDL40411Noridian Healthcare Solutions, LLCUpdated Aug 21, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "A1AT Genotyping", any status and sponsor, newest update first.
No registered device study names "A1AT Genotyping".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "A1AT Genotyping", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code PZH
0 reports: 0 malfunction, 0 injury, 0 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "A1AT Genotyping"[tiab]. The summary above synthesizes these.
- Feasibility of a genotyping system for the diagnosis of alpha1 antitrypsin deficiency: a multinational cross-sectional analysis.
Lopez-Campos JL, Osaba L, Czischke K, et al. · Respir Res · 2022Observational Study
- Distribution of alpha1 antitrypsin rare alleles in six countries: Results from the Progenika diagnostic network.
Lopez-Campos JL, Rapun N, Czischke K, et al. · Hum Genomics · 2023Research Support, Non-U.S. Gov't
- Diagnosing Alpha-1-Antitrypsin Deficiency Using A PCR/Luminescence-Based Technology.
Veith M, Klemmer A, Anton I, et al. · Int J Chron Obstruct Pulmon Dis · 2019Comparative Study, Evaluation Study
- Update on and future perspectives for the diagnosis of alpha-1 antitrypsin deficiency in Brazil.
Jardim JR, Casas-Maldonado F, Fernandes FLA, et al. · J Bras Pneumol · 2021
- Alpha-1-Antitrypsin Pi*MZ variant increases risk of developing hepatic events in nonalcoholic fatty liver disease patients.
Murali AR, Prakash S, Sanchez AJ · Clin Res Hepatol Gastroenterol · 2023
- Prevalence of genetic mutations in Alpha-1 antitrypsin in patients with difficult-to-treat asthma in Colombia.
Alí-Munive A, Chacón JL, Prada L, et al. · BMC Pulm Med · 2025Multicenter Study
- Molecular diagnosis of alpha1-antitrypsin deficiency: A new method based on Luminex technology.
Ottaviani S, Barzon V, Buxens A, et al. · J Clin Lab Anal · 2020
- [Place of genotyping in addition to the phenotype and the assay of serum α-1 antitrypsin].
Joly P, Francina A, Lacan P, et al. · Ann Biol Clin (Paris) · 2011Evaluation Study, Validation Study
- Unusually difficult clinical presentation of an infant suffering from congenital Cytomegalovirus (CMV) infection combined with alpha 1-antitrypsin (A1AT) deficiency.
Potočnjak I, Te¡ovik G, Kuna AT, et al. · Biochem Med (Zagreb) · 2014Case Reports
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.